Cross-Market Price Comparison
| Other Listed Market | Shenzhen (SZSE) — 康龙化成 |
|---|---|
| Other Market Stock Code | 300759 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 康龍化成(北京)新藥技術股份有限公司 |
|---|---|
| Stock Code | 03759 |
| Company Full Name | 康龍化成(北京)新藥技術股份有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要經營醫藥研發服務平臺，提供實驗室服務、ＣＭＣ（化學、制造及控制）服務、臨床研究服務，以及大分子和細胞與基因治療服務。 |
| Listing Date | 2019-11-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區泰河路6號1幢8層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.pharmaron.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 39.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 27.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 2,301,589,950 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 42.25 |
|---|---|
| First Day Open | HK$ 43.45 |
| First Day Change | 6.96% |
| First Day Volume | 51976500.0 |
| First Day Turnover | 2226200000.0 |
Use of Proceeds
| Use of Proceeds | 1、約1,303.3百萬港元（或所得款項凈額約30%）將用于擴展中國實驗室及生產設施的產能及能力； 2、約434.4百萬港元（或所得款項凈額約10%）撥付美國及英國業務的進一步擴張； 3、約868.8百萬港元（或所得款項凈額約20%）將用于建立有關研發生物制劑的醫藥研發服務平臺； 4、約651.6百萬港元（或所得款項凈額約15%）將用于擴展臨床開發服務實力及能力； 5、約651.6百萬港元（或所得款項凈額約15%）將用于透過潛在收購在美國、歐洲、日本或中國提供醫藥研發服務且擁有尖端研發技術的合同研發服務及合同生產服務公司及/或其業務，來擴展我們的產能及/或能力； 6、約434.4百萬港元（或所得款項凈額約10%）將用于一般企業用途及用作營運資金。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
高盛（亚洲）有限责任公司 CE ACC536
中信证券（香港）有限公司 CE AAK249
东方融资（香港）有限公司 CE BDN128
Overall Coordinators (3)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
东方证券（香港）有限公司 CE AVD362
Joint Bookrunners (4)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
东方证券（香港）有限公司 CE AVD362
华兴证券（香港）有限公司 CE AZX839
Joint Lead Managers (3)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
东方证券（香港）有限公司 CE AVD362
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 195,809,400 HKD | — | 4.25% | — | 6 months | 2020-05-28 |
| 2 | Lake Bleu Prime Healthcare Master Fund Limited | 313,298,200 HKD | — | 6.81% | — | 6 months | 2020-05-28 |
| 3 | Oaktree Funds | 195,809,400 HKD | — | 4.25% | — | 6 months | 2020-05-28 |
| 4 | OrbiMed Funds | 234,973,650 HKD | — | 5.10% | — | 6 months | 2020-05-28 |
| 5 | 中国国有企业结构调整基金股份有限公司 | 313,298,200 HKD | — | 6.81% | — | 6 months | 2020-05-28 |
Directors & Management
| Chairman | 樓柏良 |
|---|---|
| Company Secretary | 麥寶文 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 中信證券股份有限公司(23.29%);樓柏良及關連人士(12.29%);樓小強及家族成員(11.31%);北京君聯同道投資管理合伙企業(5.04%) |
|---|
